

I hereby certify that this correspondence is being transmitted by facsimile to Patent Technology Center 1600,  
Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, at 703-872-9306 on 30 December 2004.

By: Carolyn C. Caires  
Printed: Carolyn C. Caires

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Chang et al.

Title: RECOMBINANT GELATINS IN VACCINES

Serial No.: 10/232,175

Filing Date: 30 August 2002

Examiner: Y. Kim

Group Art Unit: 1644

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TERMINAL DISCLAIMER**

Sir:

FIBROGEN, INC., with its place of business at 225 Gateway Boulevard, South San Francisco CA 94080, is the Assignee of 100 percent interest in and is the owner of U.S Patent Application Serial No. 10/232,175, filed 30 August 2002, entitled " RECOMBINANT GELATINS IN VACCINES," as evidenced by the Assignment recorded in the United States Patent and Trademark Office on 13 March 2001, at Reel 011646, Frame 0232, in prior application U.S. Serial No. 09/710,249, from which the present application claims priority under 35 U.S.C. 120. Pursuant to 37 C.F.R. § 1.321(c), FIBROGEN, INC., the owner, disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on co-pending U.S. Patent Application Serial No. 09/710,239, filed on 10 November 2000, as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said co-pending application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the co-pending application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the co-pending application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors, or its assigns.


In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said co-pending application, as the term of any patent granted on said co-pending application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the co-pending application, in the event that any such patent granted on the co-pending application expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Applicants believe that no fee is due with this communication. If, however, the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge any necessary fees to Deposit Account No. 50-0811. **This form is enclosed in duplicate.** If there are any questions regarding this communication, please call the undersigned at 650-866-7200.

Respectfully submitted,

DATE: 03 Dec. 2004


  
James E. Nesbitt, Ph.D.  
Reg. No. 54,575

FIBROGEN, INC.  
225 Gateway Boulevard  
South San Francisco CA 94080  
Main: 650-866-7200  
Direct: 650-866-7289  
Facsimile: 650-866-7292

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450 on 9 December 2004.

By: Carolyn C. Cairns  
Printed: Carolyn C. Cairns

PTO/SB/17 (01-03)  
Approved for use through 04/30/2003. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 510.00

## Complete if Known

U.S. Serial No.	09/710,239
Filing Date	10 November 2000
Applicant(s)	Chang et al.
Examiner Name	C. Kam
Art Unit	1653
Docket No.	FP0400 US

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit  
Account  
Number  
Deposit  
Account  
Name

50-0811

FibroGen, Inc.

The Commissioner is authorized to: (check all that apply)

☒ Charge any fee(s) indicated below ☒ Credit any overpayments  
☒ Charge any additional fee(s) during the pendency of this application  
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing fee	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1) (\$)			0.00

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Highest previously Paid for	Fee from below	Fee Paid
Total Claims	47	-20** = 65	X = 0.00
Independent Claims	45	-3** = 56	X = 0.00
Multiple Dependent			

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 84	2201 42	Independent claims in excess of 3
1203 280	2203 140	Multiple dependent claim, if not paid
1204 84	2204 42	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	510.00
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 510.00

## SUBMITTED BY

Name (Print/Type)	Leanne C. Price, Esq.	Registration No. (Attorney/Agent)	42,090	Telephone	650-866-7200
Signature		Date	9 Dec 04		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.